Real-world evidence collected in the US has confirmed the efficacy of Takeda Pharmaceutical Co. Ltd.’s best-selling product, Entyvio (vedolizumab), in the treatment of ulcerative colitis and Crohn’s disease, as the Japanese company embraces such evidence as part of its turnaround of its pharmaceutical business.
Takeda has been reconfiguring its business over the past several years partly as a result of a former best-selling product,...
Welcome to Scrip
Create an account to read this article
Already a subscriber?